{
    "Trade/Device Name(s)": [
        "Clearview\u00ae Exact II Influenza A & B Test"
    ],
    "Submitter Information": "Binax, Inc., d/b/a Inverness Medical",
    "510(k) Number": "K092349",
    "Predicate Device Reference 510(k) Number(s)": [
        "K062109"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "GNX"
    ],
    "Summary Letter Date": "April 30, 2010",
    "Summary Letter Received Date": "May 3, 2010",
    "Submission Date": "May 7, 2010",
    "Regulation Number(s)": [
        "21 CFR 866.3300"
    ],
    "Regulation Name(s)": [
        "Influenza Virus Serological Reagents"
    ],
    "Analyte Class(es)": [
        "virology"
    ],
    "Analyte(s)": [
        "Influenza A nucleoprotein antigen",
        "Influenza B nucleoprotein antigen"
    ],
    "Specimen Type(s)": [
        "Nasal swab"
    ],
    "Specimen Container(s)": [
        "Coated Reaction Tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Clearview Exact II Test Strip"
    ],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow immunoassay"
    ],
    "Methodologies": [
        "Antigen detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Test Strip"
    ],
    "Document Summary": "FDA 510(k) summary for Clearview Exact II Influenza A & B rapid lateral flow immunochromatographic antigen assay for nasal swab specimens",
    "Indications for Use Summary": "Qualitative detection of influenza A and B nucleoprotein antigens in nasal swabs from symptomatic patients to aid in rapid differential diagnosis of influenza A and B viral infections; negative results should be confirmed by cell culture and not be solely used for treatment or management decisions.",
    "fda_folder": "Microbiology"
}